Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 569

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 569
---
 results of operations or cash flows.

Legal fees and other costs associated with such actions are expensed as incurred. The Company assesses, in conjunction with its legal counsel, the need to record a liability for litigation and contingencies. Litigation accruals are recorded when and if it is determined that a loss related matter is both probable and reasonably estimable. Material loss contingencies that are reasonably possible of occurrence, if any, are subject to disclosure. As of September 30, 2024, there was no litigation or contingency with at least a reasonable possibility of a material loss. No losses have been recorded during the three and nine months ended September 30, 2024 and 2023, respectively, with respect to litigation or loss contingencies.

Note 7 – Merger Agreement and Contribution and Exchange Agreements

FutureTech II Acquisition Corp. Merger Agreement

On September 16, 2024, Longevity entered into a Merger Agreement with FutureTech II Acquisition Corp. (“FutureTech II”). Pursuant to the Merger Agreement, the parties thereto will enter into a business combination transaction (the “Business Combination” and together with the other transactions contemplated by the Merger Agreement, the “Transactions”), pursuant to which, among other things, (i) Longevity will consummate the Target Acquisitions upon the terms and subject to conditions set forth therein and pursuant to the Contribution and Exchange Agreements (as defined therein), and (ii) immediately following the consummation of the Target Acquisitions, Longevity will merge with and into Merger Sub (the “Merger”) with Longevity as the surviving company of the Merger. Following the Merger, Longevity will be a wholly-owned subsidiary of the FutureTech II. At the closing of the Transactions (“Closing”), FutureTech II will change its name to Longevity Biomedical, Inc., and its common stock is expected to list on Nasdaq under the ticker symbol “LBIO.”

The aggregate consideration (the “Merger Consideration”) to be paid to the holders of Longevity common stock, par value $0.0001 per share (the “Longevity Common Stock”), at the Closing will consist of a number of shares of FutureTech II common stock, par value $0.0001) equal to (a) (i) $100,000,000 minus (ii) the value of each outstanding option (whether vested or unvested)s to purchase Longevity Common Stock that is converted into a new FutureTech II option in